<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[Biotek-snakken — November 2018]]></title><description><![CDATA[<p dir="auto">Jkj@. Hvad mener du om Paratek lige i øjeblikket? Synes det ligner den case jeg snakkede om, at der historisk er langt til indtjening på antibiotika.. eller at markedet tænker det sådan. Den er ihvertfald billig lige nu.. nede i 7$</p>
]]></description><link>https://dev.proinvestor.com/forum/topic/401377/biotek-snakken-november-2018</link><generator>RSS for Node</generator><lastBuildDate>Mon, 08 Jun 2026 07:59:07 GMT</lastBuildDate><atom:link href="https://dev.proinvestor.com/forum/topic/401377.rss" rel="self" type="application/rss+xml"/><pubDate>Mon, 05 Nov 2018 14:56:18 GMT</pubDate><ttl>60</ttl><item><title><![CDATA[Reply to Biotek-snakken — November 2018 on Thu, 29 Nov 2018 07:46:07 GMT]]></title><description><![CDATA[<p dir="auto">Hvorfor giver det her ikke anledning til en kursstigning.. nuevolution falder faktisk! <a href="https://nuevolution.com/amgen-exercises-its-opt-in-right-in-the-second-preclinical-cancer-program-from-the-nuevolution-collaboration/" rel="nofollow ugc">https://nuevolution.com/amgen-exercises-its-opt-in-right-in-the-second-preclinical-cancer-program-from-the-nuevolution-collaboration/</a></p>
]]></description><link>https://dev.proinvestor.com/forum/post/8057044</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/8057044</guid><dc:creator><![CDATA[Jazzz]]></dc:creator><pubDate>Thu, 29 Nov 2018 07:46:07 GMT</pubDate></item></channel></rss>